The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancerRaffaella Soldi, Sunil Sharma, Tithi Ghosh et al.|PLoS ONE|2020Cited by 82
MondoA-Mlx Transcriptional Activity Is Limited by mTOR-MondoA InteractionMohan R. Kaadige, Donald E. Ayer|Molecular and Cellular Biology|2014Cited by 41
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cellsSumati Gupta, Sunil Sharma, Kelly Doyle et al.|Oncotarget|2018Cited by 27
Abstract 3077: Preclinical studies of SR-8314, a highly selective ENPP1 inhibitor and an activator of STING pathwayAlexis Weston, Sunil Sharma, Mohan R. Kaadige et al.|Cancer Research|2019Cited by 19
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancerRaffaella Soldi, Sunil Sharma, Tithi Ghosh et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 19